
Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 70
Selected: 0
NCT ID | Title | ||
---|---|---|---|
NCT03307746 | A Combination of Rituximab and Varlilumab Immunotherapy in Patients with B-cell Lymphoma | ||
NCT04930783 | NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma | ||
NCT06727552 | A Study of Barzolvolimab in Patients With Atopic Dermatitis | ||
NCT00412828 | A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV Melanoma | ||
NCT04491084 | FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy | ||
NCT02543645 | A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer | ||
NCT02200380 | A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs | ||
NCT05368285 | A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria | ||
NCT02166905 | DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission | ||
NCT00648102 | Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian Cancer | ||
NCT05029999 | CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer | ||
NCT02642016 | A Study to Evaluate the Safety and Pharmacokinetics of CDX-0158 in Adult Patients With Advanced Solid Tumors | ||
NCT01094496 | A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study) | ||
NCT02413827 | A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma | ||
NCT03789097 | Vaccination With Flt3L, Radiation, and Poly-ICLC | ||
NCT03067935 | Individual Patient Expanded Access-Glembatumumab Vedotin | ||
NCT02335918 | A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors | ||
NCT06366750 | A Study of Barzolvolimab in Patients With Prurigo Nodularis | ||
NCT01465139 | A Study to Evaluate CDX-301 (rhuFlt3L) in Healthy Volunteers | ||
NCT03068650 | Expanded Access (Compassionate Use) Treatment Protocol Rindopepimut | ||
NCT03329950 | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | ||
NCT01997333 | Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer | ||
NCT02837991 | A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma | ||
NCT04364230 | Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma) | ||
NCT03473691 | Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast Cancer | ||
NCT02284971 | Pilot Study of SBRT and CDX-1127 in Prostate Cancer | ||
NCT03804944 | Converting HR+ Breast Cancer Into an Individualized Vaccine | ||
NCT05405660 | A Study of CDX-0159 in Patients With Chronic Inducible Urticaria | ||
NCT02270372 | Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer | ||
NCT00704158 | Study of CR011-vcMMAE to Treat Locally Advanced or Metastatic Breast Cancer | ||
NCT06650761 | A Phase I Study of CDX-622 | ||
NCT02839265 | FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancer | ||
NCT03617328 | Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma | ||
NCT02302339 | A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma | ||
NCT00323518 | A Phase II Controlled Trial of Velafermin for Prevention of Oral Mucositis | ||
NCT01480479 | Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma | ||
NCT00104065 | Safety and Efficacy of CG53135-05 in the Prevention of Oral Mucositis in Patients Receiving Bone Marrow Transplant | ||
NCT04538794 | A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria | ||
NCT05349890 | Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T) | ||
NCT05231122 | Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer | ||
NCT01156753 | A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer | ||
NCT05788484 | A Study of CDX-585 in Patients With Advanced Malignancies | ||
NCT04440943 | A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies | ||
NCT00458601 | Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme | ||
NCT02386111 | A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma | ||
NCT00948961 | A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1 | ||
NCT05774184 | A Study of CDX-0159 in Patients With Eosinophilic Esophagitis | ||
NCT03688178 | DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab | ||
NCT03835533 | Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations | ||
NCT06445023 | A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria |